LifeMD, Inc. is a direct-to-patient healthcare company providing virtual medical care and pharmacy services through a vertically integrated platform. The company operates three consumer healthcare brands, with LifeMD serving as the flagship virtual primary care and specialty platform. Its services include urgent and chronic care, weight management, men's and women's health, hormone optimization, mental health, dermatology, and cardiology. LifeMD utilizes a proprietary technology platform that integrates a 50-state affiliated provider network, a nationwide pharmacy network, and a wholly-owned commercial pharmacy located in Lancaster, Pennsylvania. The company offers prescription and over-the-counter treatments, laboratory diagnostics, and wellness coaching via desktop and mobile applications. Since June 2024, LifeMD has accepted commercial and government health insurance for virtual primary care services, including obesity-related care. The company employs AI-enabled clinical and operational technologies to support diagnosis, treatment, prescription fulfillment, and ongoing care management. LifeMD serves patients across the United States, offering synchronous and asynchronous virtual consultations through licensed physicians and nurse practitioners.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Healthcare Plans Homepage lifemd.com
Sector Healthcare IR page ir.lifemd.com
Tags
telehealth, virtual primary care, weight management, men's health, women's health, hormone health, mental health, dermatology, cardiology, pharmacy services, subscription model, glp-1 medications, LifeMD, LifeMD+, Wegovy, Zepbound, metformin, bupropion, topiramate
Press page —

Metrics

Valuation  
Market cap $ 139.942M
Market cap (USD) $ 139.942M
P/E 74.95
PEG —
P/BV -241.42
P/S 0.95
P/OCF -13.07
P/FCF -12.48
Dividend yield —
Turnover / mcap —
Returns  
ROE 62.0%
ROI —
ROIC —
Profit margin 7.4%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 13
Quality score -26.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 194.055M 212.454M 152.547M 119.034M 92.876M 37.294M 83.553K 42.515K 5.055M 5.239M 1.219M 714.158K 808.363K 673.778K
Net profit 14.354M -18.882M -20.596M -45.536M -60.898M -58.647M -3.137M -1.241M -1.206M -1.108M -61.992K -460.485K -268.262K -445.649K
Free cash flow 6.41M 16.022M 8.616M -23.302M -33.333M — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 3.41 4.95 8.29 1.94 3.87 11.8 11.8 — — — — — — —
Price performance 12m -0.31 -0.4 3.27 -0.5 -0.67 0 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 444,743 398,770 99,053 97,448 648,421 980,055 2.83M 5.28M 8.22M 9.31M
↳ YoY growth +188.0% -10.3% -75.2% -1.6% +565.4% +51.1% +189.2% +86.2% +55.7% +13.2%
↳ 5y CAGR +65.0% +51.7% +5.0% +45.4% +33.2% +17.1% +48.0% +121.5% +142.8% +70.4%
Lease liabilities (USD) — — — 29,978 285,323 1.79M 1.33M 677,029 6.77M 6.32M
Cash and deposits (USD) 182,561 141,379 180,093 1.11M 9.18M 41.3M 3.96M 33.1M 35M 36.8M
Intangible assets (USD) — — 1.01M 675,452 339,840 19,761 3.83M 3.01M 2.03M 262,334
Right-of-use assets (USD) — — — 23,625 274,437 1.75M 1.21M 594,897 6.4M 5.27M
Cash flow detail
Operating cash flow (USD) -407,914 -817,216 -905,518 251,408 -12.1M -33.1M -22.9M 8.82M 17.5M 8.28M
Purchases of property, plant and equipment (USD) — — — — — -247,365 -366,633 -203,814 -1.49M -1.87M
Purchases of intangible assets (USD) — — -100,000 — — -22,231 -4M -148,868 -3,798 —
Change in receivables (cash effect) (USD) -361,443 95,092 29,137 1,605 -550,973 17,702 -2.19M -2.44M -2.94M 1.15M
Change in inventories (cash effect) (USD) -99,219 -546,891 -341,358 72,557 -314,199 -409,823 -2.18M 405,746 -713,095 23,782
Change in payables (cash effect) (USD) — — — — — -893,956 1.25M 978,062 4.92M 3.24M
Dividends paid (cash effect) (USD) — — — — — -871,476 -3.11M -3.11M -3.11M -3.11M
Share buybacks (cash effect) (USD) — -76,648 — — — — — — — -270,000
Interest paid (cash effect) (USD) -13,650 -4,723 -4,383 -80,660 -1.67M -435,048 -189,000 -2.15M -2.53M -1.46M
Income taxes paid (cash effect) (USD) — — — — — — — — -214,211 -587,000
Share-based compensation (USD) 587,991 162,741 273,570 733,215 18.7M 12.1M 13.7M 12.5M 12.2M 10.5M
Operating cash flow before change in receivables (USD) -46,471 -912,308 -934,655 249,803 -11.6M -33.1M -20.7M 11.3M 20.5M 7.13M
Free cash flow (OCF - PPE - intangibles) (USD) — — — — — -33.4M -27.3M 8.47M 16M 6.41M
Income detail
Provision for credit losses (USD) 71,136 -49,119 — — 133,470 — — — — —
Credit cost ratio (credit losses / average receivables) (%) 23.7% 11.6% — — 35.8% — — — — —
Reported May 24, 2017 Apr 1, 2019 Apr 1, 2019 Mar 30, 2020 Mar 30, 2021 Mar 22, 2023 Mar 22, 2023 Mar 11, 2024 Mar 10, 2026 Mar 10, 2026

Operating KPIs — quarters

KPI Jun 26
Paid subscribers YoY growth (company-stated) +20.0%
Reported Aug 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 9, 2026, LifeMD, Inc. (the “Company”) and its subsidiaries LFMD Pharmacy Holdings, LLC, LFMD Pharmacy Holdings 1, LLC, and LFMD Pharmacy Services, LLC (collectively, the “Borrower”) entered into and closed on a Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P., as a lender and as administrative agent and collateral agent, and Avenue Growth Lending Fund III, L.P. (together with Avenue Venture Opportunities Fund II, L.P., the “Lenders”), and a Supplement to the Loan and Security Agreement (the “Supplement,” and together with the Loan and Security Agreement, the “Loan Agreement”), pursuant to which the Lenders made a loan to the Borrower in an aggregate principal amount of $12.5 million (the “Loan”), secured by a security interest in substantially all of the Borrower’s assets.

Through an exclusive collaboration with LifeMD, eligible AT&T wireless and fiber customers receive a complimentary LifeMD membership, a $228 annual value, with on-demand access to a nationwide virtual care and pharmacy platform.

Key Takeaways:

● More than 100 million eligible AT&T wireless and fiber customers will receive complimentary access to LifeMD’s virtual care and pharmacy platform.

● The $19-per-month LifeMD membership fee will be fully waived, a value of $228 per year.

● Members can connect with providers for everyday health needs and prescriptions, with many medications shipped directly from LifeMD’s pharmacy.

● The benefit is available through AT&T’s &More program, which allows members to unlock savings and special offers.

What’s the News: AT&T is delivering more value to eligible wireless and fiber customers through an exclusive collaboration with LifeMD, a leading virtual care and pharmacy services provider. Eligible customers receive a complimentary LifeMD membership, connecting them to a nationwide virtual care and pharmacy platform that offers convenient access to healthcare from virtually anywhere.

On August 5, 2026, LifeMD, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.

Regulation FD Disclosure

The Company hereby furnishes an investor presentation (the “Presentation”), which it expects to use in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others commencing on August 5, 2026. The Presentation is furnished herewith as Exhibit 99.2 and may also be found on the Company’s website at https://lifemd.com.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this Current Report that is required to be disclosed solely by reason of Regulation FD. The information contained in the Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time.

Prompts

LifeMD, Inc. (ticker LFMD), listed in United States.

Company History

Date Change Detail
Feb 25, 2021 Renamed CONVERSION LABS, INC. → LIFEMD, INC.
Jun 27, 2018 Renamed IMMUDYNE, INC. → CONVERSION LABS, INC.

ETFs Holding LifeMD, Inc.

ETF Weight in ETF Shares Market value As of
SQLV 0.13% 8,863 $ 36.604K Jun 30, 2026
RESM 0.01% 68 $ 280.84 Jun 30, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
LFMD canonical Common share — US nasdaq 2.90 USD 2026-09-30
LFMDP Preferred — US nasdaq — —